Form 8-K - Current report:
SEC Accession No. 0001628280-25-038981
Filing Date
2025-08-07
Accepted
2025-08-07 17:03:40
Documents
14
Period of Report
2025-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dna-20250807.htm   iXBRL 8-K 24884
2 EX-99.1 ex991earningspr.htm EX-99.1 275979
6 GRAPHIC logo.jpg GRAPHIC 4122
  Complete submission text file 0001628280-25-038981.txt   448456

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dna-20250807.xsd EX-101.SCH 1813
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dna-20250807_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dna-20250807_pre.xml EX-101.PRE 13071
16 EXTRACTED XBRL INSTANCE DOCUMENT dna-20250807_htm.xml XML 2828
Mailing Address 27 DRYDOCK AVENUE 8TH FLOOR BOSTON MA 02210
Business Address 27 DRYDOCK AVENUE 8TH FLOOR BOSTON MA 02210 (877) 442-5362
Ginkgo Bioworks Holdings, Inc. (Filer) CIK: 0001830214 (see all company filings)

EIN.: 872652913 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)